USPTO serial 79379105
V VETTER
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 24, 2024
- Examiner
- MARTIN, JENNIFER MCGARRY
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with V VETTER?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Vetter Pharma-Fertigung GmbH & Co. KG
DE
Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG
DE
Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
Vetter Pharma-Fertigung GmbH & Co. KG
DE
Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
M. Scott Alprin
M. Scott Alprin Alprin Law Offices, P.C.5 Pinehurst Circle, N.W.Washington, DC 20015United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and medicines for the prevention of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, oral and laryngeal disease, optical and cranial disorders; solutions to be taken orally, sterile solutions and injection solutions for medical purpose for treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, oral and laryngeal disease, optical and cranial disorders; eyedrops, contact lens solutions; swabs for medical purposes; plasters, materials for dressings, namely, medical plasters; filled medical injection systems, for treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, oral and laryngeal disease, optical and cranial disorders in particular syringes and instruments for injections, injectors, auto-injectors and single-chamber and dual-chamber disposable syringes; packaging units packaged individually or in combination with one another for medical and medical technology purposes, namely, packaging units containing prefilled prepared syringes, disposable syringes, disposable cannulae, ampoules and medicine vials for treatment of infections, cancer, depression, heart disease, vascular disease, intestinal disorder, lung and bronchial disfunction, liver disfunction, oral and laryngeal disease, optical and cranial disorders | ACTIVE | — |
| 010 | Empty medical injection apparatus, namely, syringes for injections, injectors, auto-injectors and single-chamber and dual-chamber disposable syringes; medicine instruments in the form of containers for administering medicines, namely, medical vials, syringes, medical cartridges and medical dual-chamber vials and syringes of glass or plastic; holders specially adapted for syringes | ACTIVE | — |
| 039 | Bottling of liquid and solid substances, in particular of pharmaceuticals, medicines and solutions, for others | ACTIVE | — |
| 042 | Pharmaceutical drug development services, namely, development of syringes and instruments for injections, injectors and packaging for the aforesaid goods, for others; chemical, physical and process engineering tests, in particular laboratory tests, namely, engineering material testing, engineering product testing, engineering quality testing for manufacturing processes; development and conducting of pharmacological and microbiological tests and processes, including for others, namely, testing of pharmaceuticals and pharmaceutical drug development services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
- Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
- Other trademarks owned by Vetter Pharma-Fertigung GmbH & Co. KG
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 039
- Other trademarks in Class 042
- Similar marks named V VETTER
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 22, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 8, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 3, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 3, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 20, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 20, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 24, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 24, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 24, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 9, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 9, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 19, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 31, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 30, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 30, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 30, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 19, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 30, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 30, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 29, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 28, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 20, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 12, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 12, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 12, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 12, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 12, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 12, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 26, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 22, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 21, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |